Oh look, another nasty problem for Valeant
The mutual fund is an investor in the company. In the suit, it accuses Valeant of running a "fraudulent scheme" through its now-defunct pharmacy, Philidor. The fund says in the suit that Valeant's secret network of pharmacies used deceptive practices to sell drugs, then hid the source of these ill-gotten gains with accounting.
All of this, T. Rowe claims, was done in an effort to preserve Valeant's drug prices.
Valeant's stock has plunged around 90% since the existence of Phildor was discovered in October. US Attorney Preet Bharara is conducting a criminal investigation into its operations, specifically into whether or not Philidor defrauded insurers.
Valeant is also under investigation from the SEC, and under scrutiny from members of the US House of Representatives and Senate because of its drug pricing practices.
- Hero MotoCorp Q4 PAT up 16.7% at ₹943.46 crore
- Goa remains top, spiritual tourism remains hot, premium accommodations grow fast — MMT’s summer travel trends for 2024
- 10 tourist places to visit in Gangtok: Distance, weather, tips
- Voltas shares drop 5% after Q4 earnings
- Yashasvi Jaiswal has got very good chance of breaking my records: Brian Lara
- Nothing Phone (2a) blue edition launched
- JNK India IPO allotment date
- JioCinema New Plans
- Realme Narzo 70 Launched
- Apple Let Loose event
- Elon Musk Apology
- RIL cash flows
- Charlie Munger
- Feedbank IPO allotment
- Tata IPO allotment
- Most generous retirement plans
- Broadcom lays off
- Cibil Score vs Cibil Report
- Birla and Bajaj in top Richest
- Nestle Sept 2023 report
- India Equity Market